Jun 2026 (Q2 FY26) — Jul 29, 2026
Anika Therapeutics Q2 FY26 — Strong Commercial Growth and Margin Expansion
Read the full callAnika Therapeutics (ANIK) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Anika Therapeutics earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 32.6 | +15.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 9.1 | +23.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 3.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$20.22 +1.20% · +$0.24
Performance +120.5% 1Y
1Y: $9.17 on 17 Oct 2025 → $20.22. High $22.03 (12 Aug 2026), low $9.13 (28 Jan 2026).
- Previous close
- $19.98
- 52-week range
- $9.13 – $22.03
- One year
- +109.53%
Overview
- Symbol
- ANIK
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Anika Therapeutics earnings calls (ANIK)
Financials
What the filings say
Net profit, year on year: +183% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 31 | 26 | 28 | 28 | 31 | 30 | 33 |
| Expenses | 19 | -5 | 19 | 19 | 19 | 19 | 24 | 18 |
| Operating profit | -0 | 28 | -4 | -4 | -3 | 1 | -5 | 3 |
| Operating margin | −0.3% | 90.9% | −16.4% | −14.8% | −11.6% | 2.1% | −18.5% | 9.1% |
| Profit before tax | 0 | 29 | -4 | -4 | -2 | 1 | -5 | 3 |
| Tax rate | 667.7% | 10.1% | −2.3% | −17.2% | −42.0% | −135.7% | −4.9% | 2.1% |
| Net profit | -30 | -22 | -5 | -4 | -2 | 0 | -5 | 3 |
| EPS ($ per share) | -2.03 | — | -0.34 | -0.28 | -0.16 | — | -0.37 | 0.25 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 218 | 245 | 221 | 226 | 211 | 128 | 72 | 61 |
| Total liabilities | 15 | 42 | 93 | 60 | 64 | 58 | 49 | 47 |
| Fixed assets | 54 | 51 | 51 | 48 | 48 | 37 | 39 | 40 |
| Investments | 70 | 27 | 3 | 30 | 35 | 26 | 24 | 24 |
| Total assets | 279 | 331 | 366 | 348 | 349 | 271 | 203 | 190 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 35 | 37 | 13 | 8 | 4 | -2 | 5 | 11 |
| Cash from investing | -50 | 40 | -71 | -3 | -7 | -5 | -8 | -0 |
| Cash from financing | -29 | -8 | -4 | -7 | -5 | -6 | -13 | -11 |
| Net cash flow | -44 | 68 | -62 | -1 | -8 | -13 | -16 | 0 |
| Capital expenditure | -5 | -3 | -2 | -5 | -7 | -5 | -8 | -7 |
| Free cash flow | 30 | 34 | 11 | 3 | -3 | -7 | -2 | 4 |
Insider filings
35 filings between Mar 9, 2026 and Aug 4, 2026.
Open market
decisions to buy or sellPurchases
$264.3K
4 purchases by 3 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 9
- Award — granted as compensation
- 11
- Option exercise — converted options into shares
- 11
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Griffin Stephen D. | $149.9K | — | Apr 30, 2026 |
| HENNEMAN JOHN B III | $73.3K | — | May 1, 2026 |
| Fischetti Gary P | $41.1K | — | Aug 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 4, 2026 | Fischetti Gary P Director | Purchase | 1,000 | $20.3K |
| Aug 3, 2026 | Fischetti Gary P Director | Purchase | 1,000 | $20.7K |
| Jun 18, 2026 | Capper Joseph H Director | Award | 10,402 | $0 |
| Jun 18, 2026 | Richard Stephen Director | Award | 10,402 | $0 |
| Jun 18, 2026 | Fischetti Gary P Director | Award | 10,402 | $0 |
| Jun 18, 2026 | HENNEMAN JOHN B III Director | Award | 10,402 | $0 |
| Jun 18, 2026 | CONLEY SHERYL L Director | Award | 10,402 | $0 |
| Jun 3, 2026 | Griffin Stephen D. President and CEO | Option exercise | 12,840 | — |
| Jun 3, 2026 | Griffin Stephen D. President and CEO | Tax withheld | 3,769 | $54.3K |
| May 1, 2026 | HENNEMAN JOHN B III Director | Purchase | 5,000 | $73.3K |
| Apr 30, 2026 | Griffin Stephen D. President and CEO | Purchase | 12,200 | $149.9K |
| Mar 15, 2026 | Colleran David EVP, General Counsel, Corp Sec | Tax withheld | 1,893 | $26.9K |
| Mar 15, 2026 | McLeod Ian SVP, CAO & Treasurer | Option exercise | 2,658 | — |
| Mar 15, 2026 | McLeod Ian SVP, CAO & Treasurer | Tax withheld | 781 | $11.1K |
| Mar 15, 2026 | Blanchard Cheryl R Director | Option exercise | 25,131 | — |
| Mar 15, 2026 | Blanchard Cheryl R Director | Tax withheld | 12,104 | $171.9K |
| Mar 15, 2026 | Colleran David EVP, General Counsel, Corp Sec | Option exercise | 6,449 | — |
| Mar 14, 2026 | Blanchard Cheryl R Director | Award | 24,520 | $0 |
| Mar 14, 2026 | Blanchard Cheryl R Director | Tax withheld | 14,728 | $209.1K |
| Mar 14, 2026 | Colleran David EVP, General Counsel, Corp Sec | Tax withheld | 4,168 | $59.2K |
| Mar 14, 2026 | McLeod Ian SVP, CAO & Treasurer | Option exercise | 3,774 | — |
| Mar 14, 2026 | Griffin Stephen D. President and CEO | Option exercise | 12,824 | — |
| Mar 14, 2026 | Griffin Stephen D. President and CEO | Award | 6,412 | $0 |
| Mar 14, 2026 | Griffin Stephen D. President and CEO | Tax withheld | 5,944 | $84.4K |
| Mar 14, 2026 | McLeod Ian SVP, CAO & Treasurer | Award | 1,161 | $0 |
| Mar 14, 2026 | McLeod Ian SVP, CAO & Treasurer | Tax withheld | 1,449 | $20.6K |
| Mar 14, 2026 | Colleran David EVP, General Counsel, Corp Sec | Option exercise | 9,388 | — |
| Mar 14, 2026 | Colleran David EVP, General Counsel, Corp Sec | Award | 4,694 | $0 |
| Mar 14, 2026 | Blanchard Cheryl R Director | Option exercise | 24,519 | — |
| Mar 9, 2026 | Blanchard Cheryl R Director | Tax withheld | 5,871 | $87.8K |
| Mar 9, 2026 | McLeod Ian SVP, CAO & Treasurer | Option exercise | 2,197 | — |
| Mar 9, 2026 | McLeod Ian SVP, CAO & Treasurer | Tax withheld | 639 | $9.6K |
| Mar 9, 2026 | Blanchard Cheryl R Director | Option exercise | 20,001 | — |
| Mar 9, 2026 | Colleran David EVP, General Counsel, Corp Sec | Option exercise | 5,465 | — |
| Mar 9, 2026 | Colleran David EVP, General Counsel, Corp Sec | Tax withheld | 1,919 | $28.7K |
| Jun 20, 2025 | Capper Joseph H Director | Award | 14,164 | $0 |
| Jun 20, 2025 | CONLEY SHERYL L Director | Award | 14,164 | $0 |
| Jun 20, 2025 | Fischetti Gary P Director | Award | 14,164 | $0 |
| Jun 20, 2025 | HENNEMAN JOHN B III Director | Award | 14,164 | $0 |
| Jun 20, 2025 | Jellison William R Director | Award | 14,164 | $0 |
| Jun 20, 2025 | Larsen Glenn R. Director | Award | 14,164 | $0 |
| Jun 20, 2025 | Richard Stephen Director | Award | 14,164 | $0 |
| Jun 20, 2025 | VOGT SUSAN L N Director | Award | 14,164 | $0 |
| Jun 3, 2025 | Griffin Stephen D. EVP, CFO & COO | Option exercise | 12,840 | $0 |
| Jun 3, 2025 | Griffin Stephen D. EVP, CFO & COO | Tax withheld | 3,769 | $43.7K |
| Mar 17, 2025 | Blanchard Cheryl R President, CEO, Director | Option exercise | 25,132 | $0 |
| Mar 17, 2025 | Blanchard Cheryl R President, CEO, Director | Tax withheld | 12,152 | $193.3K |
| Mar 17, 2025 | Colleran David EVP, General Counsel, Corp Sec | Option exercise | 6,448 | $0 |
| Mar 17, 2025 | Colleran David EVP, General Counsel, Corp Sec | Tax withheld | 1,893 | $30.1K |
| Mar 17, 2025 | Nunes Anne SVP, Chief Operations Officer | Option exercise | 3,637 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Anika Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Anika Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading